1998 clinical practice guidelines for the management of diabetes in Canada
S. J. Meltzer, Committees. Steering(Unknown), Hertzel C. Gerstein(McMaster University), David C.W. Lau(University of Calgary), Donna Lillie, Lawrence A. Leiter(St. Michael's Hospital), Bernard Zinman(Mount Sinai Hospital), Sora Ludwig, J.‐F. Yale, Denis Daneman(Hospital for Sick Children)
Canadian Medical Association Journal
October 20, 1998
Cited by 379
Related Papers
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
|New England Journal of Medicine|2015|11.9k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
|New England Journal of Medicine|2016|3.6k
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
|New England Journal of Medicine|2015|2.6k